44.20

0.76% -0.34

Vericel Corp (VCEL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vericel Corp stock is traded at $44.20, with a volume of 276.05K. It is down -0.76% in the last 24 hours and down -4.10% over the past month. Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Previous Close:

$44.54

Open:

$44.53

24h Volume:

276.05K

Relative Volume:

0.48

Market Cap:

$2.26B

Revenue:

$292.09M

Net Income/Loss:

$21.46M

P/E Ratio:

108.04

EPS:

0.4091

Net Cash Flow:

$47.49M

1W Performance:

-1.97%

1M Performance:

-4.10%

6M Performance:

+22.91%

1Y Performance:

+23.57%

1-Day Range:

$43.65

$44.55

1-Week Range:

$43.15

$46.13

52-Week Range:

$28.95

$49.32

Vericel Corp Stock (VCEL) Company Profile

Name

Vericel Corp

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(734) 930-5555

Address

64 SIDNEY ST., CAMBRIDGE, MA

Employee

398

Twitter

@VericelCorp

Next Earnings Date

2026-07-30

Latest SEC Filings

VCEL's Discussions on Twitter

Compare VCEL vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCEL Vericel Corp	44.20	2.29B	292.09M	21.46M	47.49M	0.4091
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Vericel Corp Stock (VCEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Downgrade	BTIG Research	Buy → Neutral
Aug-09-24	Initiated	Canaccord Genuity	Buy
Jun-20-24	Initiated	TD Cowen	Buy
Jan-25-24	Upgrade	Truist	Hold → Buy
Aug-08-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Nov-09-22	Downgrade	Truist	Buy → Hold
Oct-14-22	Resumed	Stephens	Overweight
Jan-11-21	Downgrade	Oppenheimer	Outperform → Perform
Dec-18-20	Initiated	Stephens	Overweight
Sep-17-20	Initiated	Truist	Buy
Oct-09-19	Initiated	H.C. Wainwright	Buy
Feb-28-19	Downgrade	Needham	Buy → Hold
Aug-08-18	Reiterated	Needham	Buy
Jul-16-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-04-18	Initiated	Leerink Partners	Outperform
Mar-06-18	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-06-18	Reiterated	Needham	Buy
Mar-05-18	Reiterated	BTIG Research	Buy
Jun-21-17	Initiated	BTIG Research	Buy
Mar-13-17	Reiterated	Needham	Buy
Dec-22-16	Initiated	Piper Jaffray	Overweight
Nov-09-16	Reiterated	Needham	Buy
Apr-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Mar-11-16	Upgrade	Needham	Hold → Buy

View All

Vericel Corp Stock (VCEL) Latest News

Aug 14, 2026

Vericel Corp Director Kevin McLaughlin Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media

Aug 14, 2026

Vericel (VCEL) director exercises 7,000 options and sells 7,000 shares - Stock Titan

Aug 14, 2026

Vericel (NASDAQ:VCEL): A Strong Growth Play With an Improving Technical Setup - ChartMill

Aug 14, 2026

Aug 13, 2026

Soleus Capital group (VCEL) discloses 2.8% Vericel ownership under 5% level - Stock Titan

Aug 13, 2026

Vericel Corporation (VCEL) Stock Forecasts - Yahoo Finance

Aug 13, 2026

Aug 12, 2026

Kevin McLaughlin (VCEL) to sell 7,000 shares after stock option exercise - Stock Titan

Aug 12, 2026

Aug 11, 2026